Back to News
Market Impact: 0.2
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Source: globenewswire.com
Healthcare & BiotechCorporate Guidance & Outlook
Topline results from the adult myositis registrational study are anticipated in 2H27, with a BLA submission planned for 1Q28. The planned submission is to include Phase 1/2 juvenile dermatomyositis data relevant to potential PRV eligibility and Phase 1/2 adult durability data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook
- AI data center firm IREN delays Microsoft AI deliveries, plans $15 billion spending push
- Airbnb says it’s launching an AI travel agent in the first half of 2027